AI Summary
This study demonstrates that ketamine helps alleviate NMDA receptor hypofunction by trapping the receptors at synapses, improving interactions with scaffolding proteins. This process reduces synaptic impairments and behavioral deficits related to anti-NMDAR encephalitis.
Villéga, Fernandes, Jézéquel et al. report that NMDAR open channel blockers, such as ketamine, favor receptor trapping at excitatory synapses through enhanced interactions with scaffolding proteins. They further show that ketamine-elicited trapping enhancement alleviates NMDAR synaptic impairments and behavioral deficits caused by autoantibodies from patients with anti-NMDAR encephalitis.